Dallas, Texas 06/26/2015 (Financialstrend) – Sorrento Therapeutics Inc (NASDAQ:SRNE) is once again the subject of research for many equity research firms. The company’s recent activity, mainly by subsidiaries, has led analysts to believe there is an upside to this therapeutics player. On Monday, MLV & Co. restated that it would continue to rate Sorrento Therapeutics as a ‘buy.’ The analyst firm has set a price target of $33.00 for the biopharmaceutical company.
On Thursday, ARK Animal Health, a subsidiary owned by Sorrento, announced receiving Minor Use/Minor Species or MUMS Drug Designation by the FDA for its ARK-001 veterinary drug. The drug is used for pain relief in dogs affected by one cancer. The present designation will allow the company to market its product, under exclusive rights for seven years. Additionally, it will also be ‘eligible’ for approvals, on conditional basis. When such conditional approval is granted, the company will have five years to provide complete data for full approval and more than five years to market the drug.
Sorrento Therapeutics Inc (NASDAQ:SRNE) subsidiary is also developing vaccines which will help fight infections from Staphylococcus, which typically causes the Pyoderma condition in dogs.
Currently, Sorrento and ARK are sharing services agreement to augment the expenses of development as many of them overlap, especially with respect to Human programs such as the API manufacturing processes.
Sorrento Therapeutics Inc (NASDAQ:SRNE) is an oncology company which is focused on clinical stage treatments for pain associated with cancers. As the biopharmaceuticals forges ahead with different partners to find successful drugs which bring pain relief, analysts continue to rate this cancer domain player a ‘buy.’
The recent developments have strongly underplayed the vast intellectual property it owns, by way of its clinical research and development of pain relieving cancer drugs. The recent diversifications into developing products which are indications or associated with immunology have also brought in investor confidence.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.